Pancreatic Cancer Research

ResearcherKarolinska University HospitalActive in the last 2 years

Thomas F. Stoop

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3328-4516; OpenAlex author ID A5045757906. Sources: OpenAlex.

Their work

Papers
44 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
212
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 14 papers · 2025: 11 papers · 2026: 16 papers

Papers 44

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. Incidence and consequences of chyle leak after pancreatectomy for pancreatic cancer. Co-author DOI 10.1016/j.hpb.2025.10.004↗
  3. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  4. Neoadjuvant multiagent chemotherapy or upfront surgery for primary resectable pancreatic cancer - A retrospective intention-to-treat analysis. Co-author DOI 10.1016/j.hpb.2026.04.451↗
  5. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  6. Patterns of treatment and survival in borderline resectable and locally advanced pancreatic cancer. First author DOI 10.1016/j.pan.2025.12.007↗
  7. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  8. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  9. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  10. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  11. Portomesenteric Venous Thrombosis After Pancreatic Cancer Surgery With Venous Resection and Reconstruction: Timing, Incidence, and Risk Factors. Co-author DOI 10.1097/sla.0000000000006605↗
  12. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  13. Implications of Neoadjuvant Therapy on Prognostic Factors in Pancreatic Ductal Adenocarcinoma: A Path Towards Personalized Prognostication. Co-author DOI 10.1097/sla.0000000000006660↗
  14. Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial. Co-author DOI 10.1097/sla.0000000000007025↗
  15. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  16. The Value of Stereotactic Radiotherapy After FOLFIRINOX in Patients with Pancreatic Cancer with Vascular Contact-A Nationwide, Retrospective Cohort Study. Co-author DOI 10.3390/cancers18040700↗
  17. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  18. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. First author DOI 10.1016/j.annonc.2024.12.015↗
  19. Pancreatic cancer. Co-author DOI 10.1016/s0140-6736(25)00261-2↗
  20. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  21. Resectability stages of pancreatic cancer: nationwide reference. Co-author DOI 10.1093/bjs/znaf120↗
  22. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  23. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. First author DOI 10.1097/sla.0000000000006650↗
  24. Surgery for Borderline Resectable and Locally Advanced Pancreatic Cancer with Arterial Encasement after Neoadjuvant Therapy: A Single-center Experience. Co-author DOI 10.1097/sla.0000000000006690↗
  25. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Co-author DOI 10.1097/sla.0000000000006910↗
  26. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  27. Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study. Co-author DOI 10.6004/jnccn.2024.7091↗
  28. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  29. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1038/s41575-023-00856-2↗
  30. Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: Trans-Atlantic Pancreatic Surg… First author DOI 10.1093/bjs/znae033↗
  31. Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients With Locally Advanced Pancreatic Cancer: A Nationwide Multicenter Study. Co-author DOI 10.1097/sla.0000000000006021↗
  32. Total versus Partial Pancreatectomy in Patients with Pancreatic Cancer Arising from Multifocal or Diffuse Intraductal Papillary Mucinous Neoplasia - A Multicen… Co-author DOI 10.1097/sla.0000000000006538↗
  33. Poor Prognostic Factors in Long-Term Survivors of Resected Pancreatic Ductal Adenocarcinoma: An International, Multicenter Cohort Study. Co-author DOI 10.1097/sla.0000000000006539↗
  34. Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study. Co-author DOI 10.1200/jco.23.01311↗
  35. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Co-author DOI 10.1245/s10434-023-14650-6↗
  36. Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRIN… First author DOI 10.1245/s10434-023-14680-0↗
  37. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone f… Co-author DOI 10.1245/s10434-023-14704-9↗
  38. ASO Author Reflections: The Value of Serum CEA for Prognostication at Staging and Response Evaluation in Patients with Localized Pancreatic Adenocarcinoma and … Co-author DOI 10.1245/s10434-023-14815-3↗
  39. Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy: A Single-Center Experience. First author DOI 10.1245/s10434-024-15591-4↗
  40. Surgical Outcome After Distal Pancreatectomy With and Without Portomesenteric Venous Resection in Patients with Pancreatic Adenocarcinoma: A Transatlantic Eval… Co-author DOI 10.1245/s10434-024-15932-3↗
  41. ASO Author Reflections: Distal Pancreatectomy With and Without Portomesenteric Venous Resection for Pancreatic Adenocarcinoma: A Transatlantic Evaluation of Pa… Co-author DOI 10.1245/s10434-024-16021-1↗
  42. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  43. Added value of 3T MRI and the MRI-halo sign in assessing resectability of locally advanced pancreatic cancer following induction chemotherapy (IMAGE-MRI): pros… Co-author DOI 10.1007/s00423-022-02653-y↗
  44. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1038/s41379-020-00683-9↗

Closest collaborators

The 25 strongest of 212 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 28 shared papers, 2021–2026 · strength 4.91
  2. Bas Groot Koerkamp · 22 shared papers, 2021–2026 · strength 4.03
  3. Marco Del Chiaro · 13 shared papers, 2023–2026 · strength 2.68
  4. Izaak Quintus Molenaar · 14 shared papers, 2024–2026 · strength 2.47
  5. Hjalmar C. van Santvoort · 13 shared papers, 2024–2026 · strength 2.39
  6. Casper H.J. van Eijck · 13 shared papers, 2024–2026 · strength 2.32
  7. Richard David Schulick · 10 shared papers, 2023–2026 · strength 2.32
  8. Ingmar Florin Rompen · 12 shared papers, 2024–2026 · strength 2.18
  9. Johanna W. Wilmink · 12 shared papers, 2021–2026 · strength 2.13
  10. Oskar Franklin · 8 shared papers, 2025–2026 · strength 1.99
  11. Christopher Lee Wolfgang · 11 shared papers, 2024–2026 · strength 1.97
  12. Ammar A. Javed · 10 shared papers, 2024–2026 · strength 1.88
  13. Ignace H. J. T. de Hingh · 10 shared papers, 2022–2026 · strength 1.71
  14. Rutger T. Theijse · 9 shared papers, 2024–2026 · strength 1.64
  15. Roeland F. de Wilde · 9 shared papers, 2024–2026 · strength 1.60
  16. Hiroyuki Ishida · 6 shared papers, 2025–2026 · strength 1.52
  17. Martijn W.J. Stommel · 9 shared papers, 2024–2026 · strength 1.51
  18. Matthew H. G. Katz · 8 shared papers, 2024–2026 · strength 1.43
  19. Geert Kazemier M · 8 shared papers, 2024–2026 · strength 1.38
  20. Freek D. Daams · 8 shared papers, 2024–2026 · strength 1.35
  21. Toshitaka Sugawara · 6 shared papers, 2023–2026 · strength 1.35
  22. Quisette P. Janssen · 7 shared papers, 2024–2026 · strength 1.28
  23. Lois A. Daamen · 7 shared papers, 2024–2026 · strength 1.27
  24. Sebastiaan Festen · 7 shared papers, 2024–2026 · strength 1.23
  25. Leonard W. F. Seelen · 7 shared papers, 2022–2026 · strength 1.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.